Care of Older Adults with Acute Myeloid Leukemia: The Role of Geriatric Assessment.

IF 4.7 2区医学 Q2 ONCOLOGY

Current Treatment Options in Oncology Pub Date : 2025-10-01 Epub Date: 2025-09-24 DOI:10.1007/s11864-025-01341-5

Ojbindra Kc, Moataz Ellithi, Vijaya Raj Bhatt

{"title":"Care of Older Adults with Acute Myeloid Leukemia: The Role of Geriatric Assessment.","authors":"Ojbindra Kc, Moataz Ellithi, Vijaya Raj Bhatt","doi":"10.1007/s11864-025-01341-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Opinion statement: </strong>Older adults with acute myeloid leukemia (AML) face disproportionately poor outcomes, driven by a combination of high-risk disease biology and functional vulnerabilities that are often overlooked by conventional oncology assessments. Geriatric assessment (GA) offers a multidimensional approach to uncover these impairments-spanning physical function, cognitive status, comorbidity burden, and emotional well-being-and provides critical information that independently predicts survival and treatment tolerance. Early studies demonstrate that GA can personalize treatment intensity decisions, inform supportive care interventions, and improve quality of life, yet its incorporation into routine AML care remains limited. Barriers to broader implementation include the need for streamlined workflows, clinician training, and large-scale validation. Future efforts should focus on integrating GA with biological markers of aging and disease to refine risk stratification, and leveraging digital tools and artificial intelligence to enhance feasibility and scalability. Ultimately, optimizing the management of older adults with AML will require a personalized, goal-concordant approach that combines GA-driven risk assessment with emerging therapeutic and supportive care strategies, ensuring that treatment intensity is matched to both disease biology and individual patient resilience.</p>","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"920-927"},"PeriodicalIF":4.7000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Treatment Options in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11864-025-01341-5","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/24 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Opinion statement: Older adults with acute myeloid leukemia (AML) face disproportionately poor outcomes, driven by a combination of high-risk disease biology and functional vulnerabilities that are often overlooked by conventional oncology assessments. Geriatric assessment (GA) offers a multidimensional approach to uncover these impairments-spanning physical function, cognitive status, comorbidity burden, and emotional well-being-and provides critical information that independently predicts survival and treatment tolerance. Early studies demonstrate that GA can personalize treatment intensity decisions, inform supportive care interventions, and improve quality of life, yet its incorporation into routine AML care remains limited. Barriers to broader implementation include the need for streamlined workflows, clinician training, and large-scale validation. Future efforts should focus on integrating GA with biological markers of aging and disease to refine risk stratification, and leveraging digital tools and artificial intelligence to enhance feasibility and scalability. Ultimately, optimizing the management of older adults with AML will require a personalized, goal-concordant approach that combines GA-driven risk assessment with emerging therapeutic and supportive care strategies, ensuring that treatment intensity is matched to both disease biology and individual patient resilience.

查看原文本刊更多论文

老年急性髓性白血病患者的护理：老年评估的作用。

观点声明：老年急性髓性白血病（AML）患者面临着不成比例的不良预后，这是由高风险疾病生物学和功能脆弱性共同驱动的，而这些通常被传统的肿瘤学评估所忽视。老年评估（GA）提供了一种多维度的方法来揭示这些损伤——跨越身体功能、认知状态、合并症负担和情绪健康——并提供了独立预测生存和治疗耐受性的关键信息。早期研究表明，GA可以个性化治疗强度决策，为支持性护理干预提供信息，并改善生活质量，但将其纳入常规AML护理仍然有限。更广泛实施的障碍包括需要简化工作流程、临床医生培训和大规模验证。未来的工作应侧重于将遗传算法与衰老和疾病的生物标志物结合起来，以完善风险分层，并利用数字工具和人工智能来提高可行性和可扩展性。最终，优化老年AML患者的管理将需要一种个性化的、目标一致的方法，将ga驱动的风险评估与新兴的治疗和支持性护理策略相结合，确保治疗强度与疾病生物学和个体患者的恢复能力相匹配。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Treatment Options in Oncology ONCOLOGY-

CiteScore

7.10

自引率

0.00%

发文量

113

审稿时长

>12 weeks

期刊介绍： This journal aims to review the most important, recently published treatment option advances in the field of oncology. By providing clear, insightful, balanced contributions by international experts, the journal intends to facilitate worldwide approaches to cancer treatment. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as endocrine tumors, lymphomas, neuro-oncology, and cancers of the breast, head and neck, lung, skin, gastrointestinal tract, and genitourinary region. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. We also provide commentaries from well-known oncologists, and an international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research.